Docetaksel
Izvor: Wikipedija
| |||
| |||
| Klinički podaci | |||
|---|---|---|---|
| Robne marke | Docefrez, Taxotere | ||
| AHFS/Drugs.com | Monografija | ||
| Identifikatori | |||
| CAS broj | 114977-28-5 | ||
| ATC kod | L01CD02 | ||
| PubChem[1][2] | 148124 | ||
| DrugBank | DB01248 | ||
| ChemSpider[3] | 130581 | ||
| KEGG[4] | C11231 
| ||
| ChEBI | CHEBI:4672
| ||
| ChEMBL[5] | CHEMBL92
| ||
| Hemijski podaci | |||
| Formula | C43H53NO14 | ||
| Mol. masa | 807,879 | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Fizički podaci | |||
| Tačka topljenja | 232 °C (450 °F) | ||
| Farmakokinetički podaci | |||
| Poluvreme eliminacije | 4 minuta | ||
| Izlučivanje | Renalno, fekalno | ||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | |||
| Način primene | Intravenozno | ||
Docetaksel (prodajni naziv Taksoter) je klinički afirmisani antimitotički hemoterapijski lek (koji ometa ćelijsku deobu). On se uglavnom koristi za tretman raka dojki, jajnika, prostate, i makrocelularnog karcinoma pluća.[6][7][8] FDA je odobrila upotrebu docetaksela za tretman pacijenata koji imaju lokalno razvijene, ili metastatičkie kancere dojki ili makrocelularne karcinome pluća koji su prošli kroz neuspešnu hemoterapiju baziranu na antraciklinima ili su u rilapsu.[9] U Evropi je odobren za tretman hormon-refraktornog raka prostate.[10]
Docetaksel je organsko jedinjenje, koje sadrži 43 atoma ugljenika i ima molekulsku masu od 807,879 Da.[11][12]
| Osobina | Vrednost |
|---|---|
| Broj akceptora vodonika | 14 |
| Broj donora vodonika | 5 |
| Broj rotacionih veza | 13 |
| Particioni koeficijent[13] (ALogP) | 2,6 |
| Rastvorljivost[14] (logS, log(mol/L)) | -7,3 |
| Polarna površina[15] (PSA, Å2) | 224,4 |
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Lyseng-Williamson KA, Fenton C (2005). „Docetaxel: a review of its use in metastatic breast cancer”. Drugs 65 (17): 2513–31. DOI:10.2165/00003495-200565170-00007. PMID 16296875.
- ↑ Clarke SJ, Rivory LP (February 1999). „Clinical pharmacokinetics of docetaxel”. Clin Pharmacokinet 36 (2): 99–114. DOI:10.2165/00003088-199936020-00002. PMID 10092957.
- ↑ A. Michael,K.Syrigos,H.Pandha (2009). „Prostate cancer chemotherapy in the era of targeted therapy”. Prostate Cancer and Prostatic Diseases 12 (1): 13–16. DOI:10.1038/pcan.2008.32. PMID 18521103.
- ↑ Anonymous. Oncology Tools: Approved Claims for microtubule inhibitors. US Food and Drug Administration. at web.archive.org (17 Sep 2006). Last modified 22 Jun 1998.
- ↑ „EU Approval for Taxotere (docetaxel) in Prostate Cancer”.[mrtav link]
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
- ↑ Ghose, A.K., Viswanadhan V.N., and Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A 102: 3762-3772. DOI:10.1021/jp980230o.
- ↑ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488-1493. DOI:10.1021/ci000392t. PMID 11749573.
- ↑ Ertl P., Rohde B., Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714-3717. DOI:10.1021/jm000942e. PMID 11020286.
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Credit:
(see original file).
